GleamWall
中文EN

MRK Merck & Co., Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 310158 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY4.9%
TTM net income YoY-87.1%
TTM EPS YoY-86.9%
Revenue 3-yr CAGR4.3%
Net income 3-yr CAGR-19.0%

Margins

Gross margin71.8%
Operating margin—
Net margin3.6%
FCF margin21.9%
EBITDA margin—

Returns

ROE5.1%
ROA1.9%
ROIC (approx.)—
Asset turnover0.51x

Leverage & solvency

Liabilities / assets66.1%
Debt / equity1.20x
Current ratio1.35x
Interest coverage—

Cash quality & payout

Operating cash flow / net income7.62x
Accruals ratio-12.4%
Payout ratio341.1%
Capex / revenue5.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$18.09B$16.61B$16.29B$16.40B$17.28B$15.81B$15.53B$15.62B
Cost of revenue$4.89B$4.39B$4.20B$5.55B$3.85B$3.56B$3.42B$3.83B
Gross profit$13.19B$12.21B$12.09B$10.85B$13.42B$12.25B$12.11B$11.80B
R&D expense$4.54B$9.74B$12.59B$3.89B$4.23B$4.05B$3.62B$4.58B
SG&A expense$2.89B$2.90B$2.70B$2.90B$2.63B$2.65B$2.55B$2.86B
Interest expense$546.00M$525.00M$479.00M$411.00M$327.00M$305.00M$313.00M$328.00M
Pretax income$5.56B-$683.00M-$3.53B$3.42B$6.75B$5.00B$5.90B$4.17B
Income tax$492.00M$654.00M$709.00M$458.00M$958.00M$571.00M$818.00M$426.00M
Net income$5.07B-$1.33B-$4.24B$2.96B$5.79B$4.43B$5.08B$3.74B
EPS (basic)2.05-0.54-1.72—2.321.762.01—
EPS (diluted)2.04-0.54-1.72—2.321.762.01—
Dividends declared per share0.850.850.850.850.810.810.810.81
Weighted avg. shares (diluted)2.48B2.47B2.47B—2.50B2.51B2.53B—
Balance sheet
Cash & equivalents$9.55B$6.85B$5.33B$14.56B$18.26B$8.07B$8.73B$13.32B
Short-term investments$100.00M$292.00M$375.00M$0$45.00M$615.00M$599.00M$447.00M
Receivables$12.74B$12.56B$12.21B$11.78B$12.12B$11.85B$10.79B$10.28B
Inventory$6.16B$6.21B$6.48B$6.66B$6.44B$6.60B$6.20B$6.11B
Current assets$38.94B$36.68B$35.02B$43.52B$47.56B$37.06B$35.50B$38.78B
PP&E, net$25.90B$25.74B$25.43B$25.32B$25.64B$25.24B$24.79B$23.78B
Goodwill$21.95B$21.58B$21.58B$21.58B$21.59B$21.59B$21.68B$21.67B
Intangibles$24.48B$24.98B$25.75B$26.68B$15.31B$15.19B$15.76B$16.37B
Total assets$132.77B$129.80B$128.69B$136.87B$129.55B$117.52B$115.12B$117.11B
Current liabilities$28.80B$27.73B$26.95B$28.33B$28.63B$26.04B$25.17B$28.42B
Short-term debt$4.09B$2.83B$2.44B$2.59B$1.41B$1.43B$1.36B$2.65B
Long-term debt$49.69B$51.08B$46.67B$46.75B$39.97B$33.97B$33.48B$34.46B
Total debt$53.78B$53.91B$49.12B$49.34B$41.37B$35.40B$34.84B$37.11B
Total liabilities$87.83B$87.82B$82.75B$84.20B$77.64B$68.46B$66.72B$70.73B
Shareholders' equity$44.89B$41.93B$45.88B$52.61B$51.85B$48.99B$48.34B$46.31B
Net debt$44.23B$47.06B$43.79B$34.77B$23.11B$27.33B$26.11B$23.79B
Cash flow statement
Operating cash flow$6.56B$5.37B$3.92B$2.86B$7.82B$3.29B$2.50B$3.45B
Capital expenditure$1.04B$893.00M$991.00M$1.03B$987.00M$764.00M$1.33B$937.00M
Free cash flow$5.52B$4.48B$2.93B$1.82B$6.83B$2.53B$1.17B$2.51B
Investing cash flow-$1.32B-$5.60B-$10.21B-$11.20B-$283.00M-$770.00M-$1.49B-$1.44B
Financing cash flow-$2.43B$1.76B-$2.98B$4.75B$2.64B-$3.56B-$5.75B-$3.01B
Depreciation & amortization$726.00M$599.00M$581.00M$1.49B$532.00M$518.00M$502.00M$522.00M
Stock-based compensation$369.00M$298.00M$185.00M$205.00M$204.00M$216.00M$195.00M$187.00M
Dividends paid$2.10B$2.14B$2.10B$2.02B$2.03B$2.08B$2.05B$1.95B
Share buybacks$653.00M$757.00M$874.00M$1.25B$1.32B$1.34B$1.16B$489.00M

Free plan shows the latest 8 periods; Pro shows all 74 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.